Abbvie Inc (ABBV)

$224.13 -9.29 (-3.98%)
Market Cap 412.54B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 23.70
Forward PE 15.53
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 9,365,800
Avg Vol 5,965,020
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 33%
Beta 0.36
Analysts Strong Sell
Price Target $245.81

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Oldpuck
Oldpuck Jan. 9 at 5:08 PM
$ABBV Some people will never get over Humira
0 · Reply
_JAKE
_JAKE Jan. 9 at 3:00 PM
$IMRX Holding my shares long term. Will keep buying if it stays this low. No stop loss or margin here, no one is getting my shares except maybe $ABBV or other big Pharm if they by us out 😀
0 · Reply
HerbertSowell1052
HerbertSowell1052 Jan. 9 at 1:18 PM
$ABBV defensive rotation plus yield makes this an easy hold in this tape
0 · Reply
ZacksResearch
ZacksResearch Jan. 9 at 12:45 PM
All eyes on $ABBV’s immunology numbers this quarter — this is the real swing factor. 👀💊 The Q4 outlook hinges on **surging Skyrizi and Rinvoq demand**, as investors look for immunology sales to **offset Humira’s past loss of exclusivity**. Can immunology fully carry the torch? Full outlook here 👉 https://www.zacks.com/stock/news/2814783/heres-what-we-expect-from-abbvies-immunology-segment-in-q4?cid=sm-stocktwits-2-2814783-teaser-28139&ADID=SYND_STOCKTWITS_TWEET_2_2814783_TEASER_28139
0 · Reply
ZacksResearch
ZacksResearch Jan. 9 at 11:45 AM
$ABBV's Skyrizi & Rinvoq driving potential Q4 growth! 🌟 💊 Skyrizi & Rinvoq sales projected at $4.87B and $2.33B, respectively, aiding AbbVie's top-line growth despite Humira's exclusivity loss. 📈 Trading at a P/E of 15.50x, below the industry average of 17.91x, offers valuation appeal. Learn about ABBV's growth potential this year 👉 https://www.zacks.com/stock/news/2814783/heres-what-we-expect-from-abbvies-immunology-segment-in-q4?cid=sm-stocktwits-2-2814783-body-28138&ADID=SYND_STOCKTWITS_TWEET_2_2814783_BODY_28138
0 · Reply
Dubbyy
Dubbyy Jan. 9 at 6:28 AM
$ABBV Pick one please either $CAPR or $SLS
1 · Reply
JInvestTrade
JInvestTrade Jan. 9 at 4:13 AM
More accurate than $DXCM and $ABBV and it works for 1 year. $SENS, $PODD, $TNDM. https://www.linkedin.com/posts/gingervieira_you-ask-hows-the-accuracy-on-the-eversense-activity-7413296265230458880-6FRr?utm_medium=ios_app&rcm=ACoAACZifW0B2JqOqHkWvrhyPzzcI0ENdA47TYM&utm_source=social_share_send&utm_campaign=share_via
2 · Reply
WangSLO
WangSLO Jan. 9 at 1:04 AM
$SLS so if $ABBV wants to get into this space and compete they'll have to buy out a different competitor right? Who better than SLS IMHO
0 · Reply
OptionsKing88
OptionsKing88 Jan. 9 at 12:23 AM
$SLS is $ABBV going to spend the same amount on buying blockbuster $SLS where it was rumored buying $RVMD for $20B
0 · Reply
CrispDry
CrispDry Jan. 8 at 11:14 PM
$ABBV we know they are willing to spend $20B on something $XBI
0 · Reply
Latest News on ABBV
AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 12:07 PM EST - 23 hours ago

AbbVie: The Dividend Does Not Lie

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

Jan 8, 2026, 7:38 AM EST - 1 day ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

RVMD

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

Jan 7, 2026, 2:58 PM EST - 1 day ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

RVMD

AbbVie Near Deal for Revolution Medicines

Jan 7, 2026, 2:48 PM EST - 1 day ago

AbbVie Near Deal for Revolution Medicines

RVMD

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Jan 7, 2026, 8:00 AM EST - 2 days ago

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 11:43 AM EST - 3 days ago

What Can Trigger A Breakout In Abbvie Stock?

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

Jan 6, 2026, 7:29 AM EST - 3 days ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ARGX NBIX

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 4 days ago

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

AbbVie: Rocky Near-Term, Positive Long-Term

Jan 4, 2026, 9:04 AM EST - 5 days ago

AbbVie: Rocky Near-Term, Positive Long-Term

My Most Important Warning To Dividend Investors For 2026

Jan 3, 2026, 7:30 AM EST - 6 days ago

My Most Important Warning To Dividend Investors For 2026

AM ARES CNI CPT ENB EPD EXR

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

Jan 1, 2026, 10:24 PM EST - 7 days ago

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

Best Dividend Aristocrats For January 2026

Dec 31, 2025, 8:47 AM EST - 9 days ago

Best Dividend Aristocrats For January 2026

ABT ADM ADP AFL ALB AMCR AOS

Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 12 days ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 21 days ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 22 days ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

AMGN AZN BMY LLY NVS PFE

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

Dec 17, 2025, 2:17 PM EST - 22 days ago

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

MSFT NFLX TWLO

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

Dec 14, 2025, 11:30 PM EST - 25 days ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ALGT CGNX COHR EOLS INSP LTH MAT

AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 4 weeks ago

AbbVie: Unique Mix Of Growth And Value

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

Dec 8, 2025, 1:30 AM EST - 4 weeks ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 3, 2025, 4:53 PM EST - 5 weeks ago

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Dec 2, 2025, 8:15 AM EST - 5 weeks ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Dec 1, 2025, 5:55 AM EST - 5 weeks ago

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 5 weeks ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Nov 28, 2025, 7:01 AM EST - 6 weeks ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Nov 25, 2025, 9:30 AM EST - 6 weeks ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 6 weeks ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 12:47 PM EST - 7 weeks ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

It's Best Time In 10 Years To Lock In Income: Our Picks

Nov 18, 2025, 9:00 AM EST - 7 weeks ago

It's Best Time In 10 Years To Lock In Income: Our Picks

ADC AVGO DG ENB EPD FDX MSFT

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 7 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD GSK JNJ LLY

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 4:31 PM EST - 7 weeks ago

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 7 weeks ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

AZN JNJ LLY MRK NVO PFE XLV

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Nov 13, 2025, 8:30 AM EST - 2 months ago

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 2 months ago

AbbVie Shares Rise To Intraday High After Key Trading Signal

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Nov 12, 2025, 8:30 AM EST - 2 months ago

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

Nov 12, 2025, 8:30 AM EST - 2 months ago

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 2 months ago

AbbVie Has Many Bullish Attributes (Technical Analysis)

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 2 months ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 2 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ALNY AMGN BMY LLY MBX MDGL MEDI

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

Nov 1, 2025, 11:15 PM EDT - 2 months ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ADP AEP AIZ AOS ATO BDX BRO

Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 2 months ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 2 months ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Oct 31, 2025, 11:47 AM EDT - 2 months ago

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 2 months ago

AbbVie: Why Q3 Confirms Its Immunology Dominance

AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 2 months ago

AbbVie Lifts Profit Outlook as Sales Rise

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

Oct 31, 2025, 8:20 AM EDT - 2 months ago

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

Oct 31, 2025, 7:54 AM EDT - 2 months ago

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 2 months ago

AbbVie Reports Third-Quarter 2025 Financial Results

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

Oct 29, 2025, 5:00 PM EDT - 2 months ago

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

Oct 29, 2025, 8:11 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 2 months ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH

Oldpuck
Oldpuck Jan. 9 at 5:08 PM
$ABBV Some people will never get over Humira
0 · Reply
_JAKE
_JAKE Jan. 9 at 3:00 PM
$IMRX Holding my shares long term. Will keep buying if it stays this low. No stop loss or margin here, no one is getting my shares except maybe $ABBV or other big Pharm if they by us out 😀
0 · Reply
HerbertSowell1052
HerbertSowell1052 Jan. 9 at 1:18 PM
$ABBV defensive rotation plus yield makes this an easy hold in this tape
0 · Reply
ZacksResearch
ZacksResearch Jan. 9 at 12:45 PM
All eyes on $ABBV’s immunology numbers this quarter — this is the real swing factor. 👀💊 The Q4 outlook hinges on **surging Skyrizi and Rinvoq demand**, as investors look for immunology sales to **offset Humira’s past loss of exclusivity**. Can immunology fully carry the torch? Full outlook here 👉 https://www.zacks.com/stock/news/2814783/heres-what-we-expect-from-abbvies-immunology-segment-in-q4?cid=sm-stocktwits-2-2814783-teaser-28139&ADID=SYND_STOCKTWITS_TWEET_2_2814783_TEASER_28139
0 · Reply
ZacksResearch
ZacksResearch Jan. 9 at 11:45 AM
$ABBV's Skyrizi & Rinvoq driving potential Q4 growth! 🌟 💊 Skyrizi & Rinvoq sales projected at $4.87B and $2.33B, respectively, aiding AbbVie's top-line growth despite Humira's exclusivity loss. 📈 Trading at a P/E of 15.50x, below the industry average of 17.91x, offers valuation appeal. Learn about ABBV's growth potential this year 👉 https://www.zacks.com/stock/news/2814783/heres-what-we-expect-from-abbvies-immunology-segment-in-q4?cid=sm-stocktwits-2-2814783-body-28138&ADID=SYND_STOCKTWITS_TWEET_2_2814783_BODY_28138
0 · Reply
Dubbyy
Dubbyy Jan. 9 at 6:28 AM
$ABBV Pick one please either $CAPR or $SLS
1 · Reply
JInvestTrade
JInvestTrade Jan. 9 at 4:13 AM
More accurate than $DXCM and $ABBV and it works for 1 year. $SENS, $PODD, $TNDM. https://www.linkedin.com/posts/gingervieira_you-ask-hows-the-accuracy-on-the-eversense-activity-7413296265230458880-6FRr?utm_medium=ios_app&rcm=ACoAACZifW0B2JqOqHkWvrhyPzzcI0ENdA47TYM&utm_source=social_share_send&utm_campaign=share_via
2 · Reply
WangSLO
WangSLO Jan. 9 at 1:04 AM
$SLS so if $ABBV wants to get into this space and compete they'll have to buy out a different competitor right? Who better than SLS IMHO
0 · Reply
OptionsKing88
OptionsKing88 Jan. 9 at 12:23 AM
$SLS is $ABBV going to spend the same amount on buying blockbuster $SLS where it was rumored buying $RVMD for $20B
0 · Reply
CrispDry
CrispDry Jan. 8 at 11:14 PM
$ABBV we know they are willing to spend $20B on something $XBI
0 · Reply
fastmoneytraders
fastmoneytraders Jan. 8 at 9:40 PM
tomorrow it will $RVMD or $ABBV in talks to buy $ERAS lol what a shit show
0 · Reply
NvidiaKing
NvidiaKing Jan. 8 at 9:18 PM
$ABBV shitty company.. I know I worked for them
1 · Reply
MarketMakerr
MarketMakerr Jan. 8 at 8:16 PM
$ABBV most volatile start to a year for this company ever
0 · Reply
mydogabbymoon
mydogabbymoon Jan. 8 at 7:59 PM
$ABBV guidance and performance f-up driving this back under 200 again?
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 8 at 7:01 PM
$ABBV Share Price: $224.66 Contract Selected: Jan 30, 2026 $225 Calls Buy Zone: $4.00 – $4.94 Target Zone: $6.55 – $8.00 Potential Upside: 55% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 8 at 6:14 PM
$SLS has conducted 3 Trials with GPS and $BMY / $MRK the Ovarian cancer trial with Opdivo was stopped Early DUE TO EFFICACY ... GPs +Keytruda Achieved Better Phase. 2 MOS Data for Plat Resistant Ovarian Cancer than Elahere $IMGN which was bought for $10.1B by $ABBV. SLS will not be a stand alone entity much longer, now that the REGAL Update Confirmed GPs is Virtually Certain to get FDA Approval -- you may not know this, but Smart Money Does. //
0 · Reply
ST4Life
ST4Life Jan. 8 at 5:42 PM
$ABBV easy come easy go
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 8 at 5:21 PM
$SLS Manipulation has completely Disconnected this rigged $3.89 Share Price from Gps' True Value. ... Offering an Investment Opportunity of a Lifetime. - $28B Total Addressable Market. - 77x ROI in this Equity at this Level. Gps will treat upwards of 100,000 AML Patients CURRENTLY in Remission- immediately upon approval - right out of the gate - very Different from Most hemeOnc drugs where treatment begins upon Diagnoses. And the Remission Maintenance Treatment Setting is Ongoing Until Disease Relapse - Years of Gps Treatment for most patients, vs very short narrow treatment windows with ALL other Heme Onc Drugs. CC0 published estimated Gps Pricing $280K per Patient for Year 1 - $110K Year 2, $70K year 3. $ABBV $BMY $RHHBY
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Jan. 8 at 5:11 PM
$ABBV what now
0 · Reply
Game_Day
Game_Day Jan. 8 at 4:48 PM
$MSTR + $NBIS 🔥 $RBLX $ABBV
0 · Reply
snaches
snaches Jan. 8 at 3:40 PM
$ABBV lol even CNBC fell for it 
0 · Reply
xtremdelt8
xtremdelt8 Jan. 8 at 2:51 PM
$ABBV Someone made good money on the fake news yesterday.
0 · Reply